<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        52-271-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIVAZAC PLUS 300MG/12.5MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />VIVAZAC&reg; PLUS is a combination of two active substances, irbesartan and hydrochlorothiazide.<br />Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.<br />Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.<br />Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.<br />The two active ingredients in VIVAZAC&reg; PLUS work together to lower blood pressure further than if either was given alone.</p><p>Therapeutic indications:<br />VIVAZAC&reg; PLUS is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take VIVAZAC&reg; PLUS</strong><br />-If you are allergic to irbesartan or any of the other ingredients of this medicine.<br />-If you are allergic to hydrochlorothiazide or any other sulfonamide-derived medicines.<br />-If you are more than 3 months pregnant. (It is also better to avoid VIVAZAC&reg; PLUS in early pregnancy).<br />-If you have severe liver or kidney problems.<br />-If you have difficulty in producing urine.<br />-If your doctor determines that you have persistently high calcium or low potassium levels in your blood.<br />-If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p><br /><strong>b. Take special care with VIVAZAC&reg; PLUS</strong><br />Talk to your doctor before taking VIVAZAC&reg; PLUS and if any of the following apply to you:<br />-If you get excessive vomiting or diarrhoea.<br />-If you suffer from kidney problems or have a kidney transplant.<br />-If you suffer from heart problems.<br />-If you suffer from liver problems.<br />-If you suffer from diabetes.<br />-If you suffer from lupus erythematosus (also known as lupus or SLE).<br />-If you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).<br />-If you are taking any of the following medicines used to treat high blood pressure:</p><p>&bull;An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.<br />&bull;Aliskiren.</p><p><br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />You must tell your doctor if you think you are (or might become) pregnant. VIVAZAC&reg; PLUS is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.<br />You should also tell your doctor:<br />-If you are on a low-salt diet.<br />-If you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide.<br />-If you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.<br />-If you are going to have an operation (surgery) or be given anesthetics.<br />-If you have changes in your vision or pain in one or both of your eyes while taking VIVAZAC&reg; PLUS. This could be a sign that you are developing glaucoma, increased pressure in your eye(s). you should discontinue VIVAZAC&reg; PLUS treatment and seek medical attention.<br />The hydrochlorothiazide contained in this medicine could produce a positive result in an anti-doping test.</p><p>Children and adolescents<br />VIVAZAC&reg; PLUS should not be given to children and adolescents (under 18 years).</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Diuretic agents such as the hydrochlorothiazide contained in VIVAZAC&reg; PLUS may have an effect on other medicines. Preparations containing lithium should not be taken with VIVAZAC&reg; PLUS without close supervision by your doctor.<br />Your doctor may need to change your dose and/or to take other precautions:<br />If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take VIVAZAC&reg; PLUS&rdquo; and &ldquo;Warnings and precautions&rdquo;).<br />You may need to have blood checks if you take:<br />-Potassium supplements.<br />-Salt substitutes containing potassium.<br />-Potassium sparing medicines or other diuretics (water tablets).<br />-Some laxatives.<br />-Medicines for the treatment of gout.<br />-Therapeutic vitamin D supplements.<br />-Medicines to control heart rhythm.<br />-Medicines for diabetes (oral agents or insulins).<br />-Carbamazepine (a medicine for the treatment of epilepsy).<br />It is also important to tell your doctor if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers, arthritis medicines, or cholestyramine and colestipol resins for lowering blood cholesterol.</p><p><strong>d. Taking VIVAZAC&reg; PLUS with food and drink</strong><br />VIVAZAC&reg; PLUS can be taken with or without food.<br />Due to the hydrochlorothiazide contained in VIVAZAC&reg; PLUS if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, especially when getting up from a sitting position.</p><p><strong>e. Pregnancy and breast-feeding<br />Pregnancy</strong><br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking VIVAZAC&reg; PLUS before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of VIVAZAC&reg; PLUS.<br />VIVAZAC&reg; PLUS is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.<br /><strong>Breast-feeding</strong><br />Tell your doctor if you are breast-feeding or about to start breast-feeding. VIVAZAC&reg; PLUS is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>f. Driving and using machines</strong><br />No studies on the effects on the ability to drive and use machines have been performed. VIVAZAC&reg; PLUS is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before&nbsp;attempting to drive or use machines.</p><p><strong>g. Important information about one of the ingredients in VIVAZAC&reg; PLUS</strong><br />VIVAZAC&reg; PLUS contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Dosage</strong><br />The recommended dose of VIVAZAC&reg; PLUS is one or two tablets a day. VIVAZAC&reg; PLUS will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.</p><p>Your doctor will instruct you how to switch from the previous treatment to VIVAZAC&reg; PLUS.</p><p><strong>Method of administration</strong><br />VIVAZAC&reg; PLUS is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). You can take VIVAZAC&reg; PLUS with or without food. In VIVAZAC&reg; PLU 150/12.5mg the score line is not intended for breaking the tablet. It is important that you continue to take VIVAZAC&reg; PLUS until your doctor tells you otherwise.<br />The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment.</p><p><strong>Children should not take VIVAZAC&reg; PLUS.</strong><br />VIVAZAC&reg; PLUS should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.</p><p><strong>a.If you take more VIVAZAC&reg; PLUS than you should</strong><br />If you accidentally take too many tablets, contact your doctor immediately.</p><p><strong>b.If you forget to take VIVAZAC&reg; PLUS</strong><br />If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><strong>c. If you stop taking VIVAZAC&reg; PLUS</strong><br />Do not stop taking VIVAZAC&reg; PLUS Tablets unless your doctor tells you to. Treatment with VIVAZAC&reg; PLUS Tablets should be stopped gradually, especially<br />if you have been taking a high dose, unless your doctor has told you otherwise.<br />Stopping treatment suddenly may cause effects such as an increase in heart rate and high blood pressure. If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Some of these effects may be serious and may require medical attention.<br />Rare cases of allergic skin reactions (rash, urticaria), as well as localized swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.<br />If you get any of the above symptoms or get short of breath, stop taking VIVAZAC&reg; PLUS and contact your doctor immediately.<br />The frequency of the side effects listed below is defined using the following convention:<br />Common: may affect up to 1 in 10 people<br />Uncommon: may affect up to 1 in 100 people</p><p>Side effects reported in patients treated with VIVAZAC&reg; PLUS were:<br /><strong>Common side effects (may affect up to 1 in 10 people):</strong><br />Nausea/vomiting.<br />Abnormal urination.<br />Fatigue.<br />Dizziness (including when getting up from a lying or sitting position).<br />Blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).</p><p>If any of these side effects causes you problems, talk to your doctor.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong><br />Diarrhoea.<br />Low blood pressure.<br />Fainting.<br />Heart rate increased.<br />Flushing.<br />Swelling.<br />Sexual dysfunction (problems with sexual performance).<br />Blood tests may show lowered levels of potassium and sodium in your blood.<br />If any of these side effects causes you problems, talk to your doctor.</p><p>Side effects reported since the launch of drug:</p><p>Some undesirable effects have been reported since marketing of drug. Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat. Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.<br />As for any combination of two active substances, side effects associated with each individual component cannot be excluded.</p><p>Side effects associated with irbesartan alone<br />In addition to the side effects listed above, chest pain and decrease in the number of platelets (a blood cell essential for the clotting of the blood) have also been reported.</p><p><br />Side effects associated with hydrochlorothiazide alone<br />&bull;Loss of appetite.<br />&bull;Stomach irritation.<br />&bull;Stomach cramps.<br />&bull; Constipation.<br />&bull;Jaundice (yellowing of the skin and/or whites of the eyes).<br />&bull;Inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting.<br />&bull;Sleep disorders.<br />&bull;Depression.<br />&bull;Blurred vision.<br />&bull;Lack of white blood cells, which can result in frequent infections, fever.<br />&bull;Decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale.<br />&bull;Kidney disease.<br />&bull;Lung problems including pneumonia or build-up of fluid in the lungs.<br />&bull;Increased sensitivity of the skin to the sun.<br />&bull;Inflammation of blood vessels.<br />&bull;A skin disease characterized by the peeling of the skin all over the body.<br />&bull;Cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions.<br />&bull;Weakness and muscles spasm.<br />&bull;Altered heart rate.<br />&bull;Reduced blood pressure after a change in body position.<br />&bull;Swelling of the salivary glands.<br />&bull;High sugar levels in the blood.<br />&bull;Sugar in the urine.<br />&bull;Increases in some kinds of blood fat<br />&bull;High uric acid levels in the blood, which may cause gout.</p><p><br />It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep this medicine out of the sight and reach of children.<br />-Do not store above 30&deg;C, Protect from Moisture.<br />-Do not use VIVAZAC&reg; PLUS after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.<br />-Do not use VIVAZAC&reg; PLUS if you notice description of the visible signs of deterioration.<br />-Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are: irbesartan and hydrochlorothiazide.</p><p><br />-VIVAZAC&reg; PLUS 150/12.5: Each film-coated tablet contains 150 mg Irbesartan and 12.5 mg Hydrochlorothiazide.<br />-VIVAZAC&reg; PLUS 300/12.5: Each film-coated tablet contains 300 mg Irbesartan and 12.5 mg Hydrochlorothiazide.<br />-VIVAZAC&reg; PLUS 300/25: Each film-coated tablet contains 300 mg Irbesartan and 25 mg Hydrochlorothiazide.</p><p>The other ingredients:<br />Lactose, Crosscarmellose sodium, Starch, Hypromellose, Microcrystalline Cellulose, Colloidal silicon dioxide, Magnesium Stearate, Opadry White O-YL 28900, Yellow Iron Oxide &amp; Red Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form is Film coated tablets
VIVAZAC® PLUS looks like
-VIVAZAC® PLUS 150/12.5: Light pink color caplet shape tablet scored on one side and plain on the other.
-VIVAZAC® PLUS 300/12.5: Peach, biconvex caplet shape tablet, embossed with U7l on one side and plain on the other.
-VIVAZAC® PLUS 300/25: Brick red color biconvex caplet shape tablet embossed with E43 on one side and plain on the other.

VIVAZAC® PLUS Tablets are packed in blisters of Aluminum /PVC/PVDC, in carton box with a multi folded leaflet.

Pack size: 30 Film Coated Tablets; (10 Film Coated Tablets /blister, 3 blisters/ pack).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer<br />The United Pharmaceutical Mfg. Co. Ltd.<br />P.O. Box 69, Amman 11591-Jordan<br />Tel: + 962 (6) 416 2901<br />Fax: + 962 (6) 416 2905<br />E-mail: upm_info@mspharma.com</p><p><br />For any information about this medicinal product, please contact the local representative<br />of the Marketing Authorization Holder:<br />Cigalah Group<br />P.O. Box 19435, Jeddah 21435 -KSA<br />Tel: +966126136740<br />Fax: + 96626148458<br />E-mail: ihamidaddin@cigalah.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in Sep., 2017; version number M3-14-0959
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة العلاجية:</p><p>فيفيزاك بلس هو مزيج من اثنين من المواد الفعالة، إربيسارتان وهيدروكلوروثيازايد.</p><p>ينتمي إربيسارتان إلى مجموعة من الأدوية المعروفة باسم مضادات مستقبلات أنجيوتنسين الثاني. أنجيوتنسين الثاني هو عبارة عن مادة تنتج في الجسم وتربط بمستقبلات في الأوعية الدموية مما يسبب في شدها و يؤدي إلى زيادة في ضغط الدم. يمنع إربيسارتان من ارتباط الأنجيوتنسين الثاني لهذه المستقبلات، مما يسبب في استرخاء الأوعية الدموية وانخفاض ضغط الدم.</p><p>هيدروكلوروثيازايد هو واحد من مجموعة الأدوية تسمى مدرات البول الثيازيدية والتي تسبب زيادة كمية البول المطروح وبالتالي يسبب خفض ضغط الدم.إن المكونين النشطين في فيفيزاك بلس تعمل معا لخفض ضغط الدم أكثر مما لو أعطيت أي مكون نشط لوحده.</p><p>الاستعمالات العلاجية:</p><p>يستعمل فيفيزاك بلس لعلاج ارتفاع ضغط الدم وذلك عندما لا يوفر العلاج مع إربيسارتان أو هيدروكلوروثيازايد لوحده السيطرة الكافية على ضغط الدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. لا تأخذ فيفيزاك بلس </strong></p><p>-إذا كنت تعاني من حساسية لاربيسارتان أو لأي من المكونات الأخرى من هذا الدواء.</p><p>-إذا كنت تعاني من حساسية لمادة هيدروكلوروثيازايد أو أي دواء أخر مشتق من السلفوناميد.</p><p>-خلال الأشهر الست الأخيرة من الحمل من الأفضل الامتناع عن تناول فيفيزاك بلس في بداية الحمل.</p><p>-إذا كان لديك مشاكل شديدة في الكبد أو في الكلى.</p><p>-إذا كان لديك صعوبة في إنتاج البول.</p><p>-إذا قرر طبيبك بأن لديك ارتفاع مستمر في مستويات الكالسيوم أو البوتاسيوم في الدم.</p><p>-تعاني من مرض السكري أو ضعف في وظائف الكلى ويتم علاجك بدواء يخفض ضغط الدم يحتوي على أليسكيرن.</p><p>&nbsp;</p><p><strong>ب. الاحتياطات عند استعمال فيفيزاك بلس </strong></p><p>-تحدث مع طبيبك قبل أخذ فيفيزاك بلس و إذا كان أي من الحالات التالية تنطبق عليك:</p><p>-إذا كنت تعاني من القيء المفرط أو الإسهال.</p><p>-إذا كنت تعاني من مشاكل في الكلى أولديك كلية مزروعة.</p><p>-إذا كنت تعاني من مشاكل في القلب.</p><p>-إذا كنت تعاني من داء السكري.</p><p>-إذا كنت تعاني من الذئبة الحمامية المعروفة أيضا باسم الذئبة أو الذئبة الحمراء الجهازية.</p><p>&nbsp;-إذا كنت تعاني من الألدوستيرونية الأساسية حالة تتعلق بارتفاع إنتاج هرمون الألدوستيرون، والذي يسبب الاحتفاظ بالصوديوم، وبالتالي زيادة ضغط الدم.(إذا كنت تتناول أي من الأدوية التالية المستخدمة في علاج ضغط الدم المرتفع:</p><p>-مثبطات الإنزيم المحول للأنجيوتنسين على سبيل المثال إنالابريل، ليسينوبريل، راميبريل، خاصة إذا كان لديك مشاكل في الكلى ذات صلة بمرض السكري.</p><p>-أليسكيرين.</p><p>&nbsp;</p><p>قد يقوم طبيبك بفحص وظائف الكلى وضغط الدم ومقدار الشوارد على سبيل المثال البوتاسيوم في الدم على فترات منتظمة.</p><p>يجب عليك إخبار الطبيب إذا كنت تعتقدين بأنك أو قد تصبحين حاملا. لا ينصح باستعمال فيفيزاك بلس في المرحلة المبكرة من الحمل ويمكن أن يتسبب في إلحاق ضرر جسيم لطفلك بعد 3 أشهر من الحمل إذا استعمل في هذه المرحلة.يجب عليك أيضا إخبار طبيبك:</p><p>-إذا كنت على نظام غذائي منخفض الاملاح.</p><p>-إذا كان لديك علامات مثل العطش غير الطبيعي، جفاف الفم، الضعف العام، والنعاس، آلام في العضلات أو تشنجات، غثيان، تقيؤ، أو ضربات قلب سريعة بشكل غير طبيعي والتي قد تشير إلى تأثير مفرط لمادة هيدروكلوروثيازايد.</p><p>-إذا واجهت حساسية زائدة في الجلد تجاه الشمس مع أعراض حروق شمسية مثل احمرار، حكة، تورم، بثور والتي تحدث بسرعة أكبر من المعتاد.</p><p>-إذا كنت ستخضع لعملية جراحية أو أن تعطى التخدير.</p><p>-إذا کان لدك تغیرات في مجال الرؤية أو الألم في أحدى أو کلا عينيك أثناء تناول فيفيزاك بلس. هذا يمكن ییأن يكون علامة على أنك ستصاب بالزرق، وزيادة الضغط في عينيك. يجب عليك التوقف عن علاج فيفيزاك بلس والتماس العناية الطبية.</p><p>هيدروكلوروثيازايد الموجود في هذا الدواء يمكن أن يعطي نتيجة إيجابية في اختبار مكافحة المنشطات.</p><p>&nbsp;</p><p>الأطفال والمراهقين</p><p>يجب عدم استعمال فيفيزاك بلس في الأطفال والمراهقين الأقل من18 عاما.</p><p>&nbsp;</p><p><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تأخذ، قد أخذت مؤخرا أو قد تأخذ أي أدوية أخرى. مدرات البول مثل هيدروكلوروثيازايد الموجودة في فيفيزاك بلس قد يكون له تأثير على الأدوية الأخرى. لا ينبغي أن تؤخذ المستحضرات التي تحتوي على الليثيوم مع فيفيزاك بلس دون إشراف دقيق من قبل الطبيب.قد يحتاج طبيبك إلى تغيير الجرعة و / أو اتخاذ احتياطات أخرى:</p><p>إذا كنت تتناول مثبطات الإنزيم المحول للأنجيوتنسين أو أليسكيرين.</p><p>قد تحتاج إلى إجراء فحوص للدم إذا كنت تتناول:</p><p>-مكملات البوتاسيوم.</p><p>-بدائل الملح التي تحتوي على البوتاسيوم.</p><p>-الأدوية المقتصدة للبوتاسيوم مثل بعض مدرات البول.</p><p>-بعض الملينات.</p><p>-أدوية علاج النقرس.</p><p>-مكملات فيتامين د العلاجية.</p><p>-أدوية السيطرة على إيقاع القلب.</p><p>-أدوية علاج مرض السكري أدوية تؤخذ عن طريق الفم أو الأنسولين.</p><p>-كاربامازيبين دواء لعلاج الصرع.</p><p>من المهم أيضا إخبار طبيبك إذا كنت تتناول أدوية أخرى لتقليل ضغط الدم، الستيرويدات،أدوية علاج السرطان، المسكنات،أدوية علاج التهاب المفاصل أو راتنجات الكولسترامين وكوليستيبول تستعمل لخفض الكولسترول في الدم.</p><p>&nbsp;</p><p><strong>د. تناول أقراص فيفيزاك بلس مع الطعام والشراب</strong></p><p>يمكن تناول فيفيزاك بلس بغض النظر عن تناول وجبات الطعام. بسبب وجود هيدروكلوروثيازايد في فيفيزاك بلس و إذا كنت تشرب الكحول أثناء العلاج مع هذا الدواء، قد يكون لديك شعور متزايد من الدوخة على الوقوف، وخصوصا عند الوقوف من وضع الجلوس.</p><p><strong>ه. الحمل والرضاعة</strong></p><p>الحمل</p><p>يجب أن تخبر طبيبك إذا كنت تعتقدين بأنك أو قد تصبح حاملا. عادة، سوف ينصحك طبيبك بالتوقف عن تناول فيفيزاك بلس قبل أن تصبحي حاملا أو بأقرب وقت ممكن بعد علمك بالحمل وينصحك باستعمال دواء اخر بدلا من فيفيزاك بلس.</p><p>لا ينصح بتناول فيفيزاك بلس في المرحلة المبكرة من الحمل ، ويجب عدم أخذه بعد الثلاث أشهر الاولى من الحمل، لأنها قد تسبب ضررا خطيرا لطفلك إذا ما استخدمت بعد الشهر الثالث من الحمل.</p><p>الرضاعة الطبيعية</p><p>أخبر طبيبك إذا كنت ترضعين رضاعة طبيعية أو على وشك البدء في الرضاعة الطبيعية. لا ينصح باستعمال فيفيزاك بلس في الأمهات المرضعات، وقد يختار طبيبك علاج آخر إذا كنت ترغبين في الرضاعة الطبيعية، خاصة إذا كان طفلك حديث الولادة أو ولد قبل الأوان.</p><p>&nbsp;</p><p><strong>و. القيادة واستعمال الآلات</strong></p><p>لم تجرى دراسات لمعرفة التأثير على القدرة على القيادة واستعمال الآلات. من غير المرجح أن يؤثر فيفيزاك بلس على قدرتك على القيادة أو استعمال الآلات. ومع ذلك، قد يحدث دوخة أو تعب أحيانا أثناء علاج ارتفاع ضغط الدم. إذا واجهت مثل هذه الاعراض، يجب عليك التحدث مع طبيبك قبل محاولة القيادة أو استعمال الآلات.</p><p><strong>ز. معلومات مهمة عن مكون من مكونات فيفيزاك بلس </strong></p><p>يحتوي فيفيزاك بلس على اللاكتوز. إذا قيل لك من قبل طبيبك أن لديك تعصب لبعض السكريات مثل اللاكتوز، اتصل بطبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. تحقق مع الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p>الجرعة الجرعة الموصى بها من فيفيزاك بلس هي قرص واحد أو اثنين يوميا.</p><p>عادة ما يوصف فيفيزاك بلس من قبل الطبيب وذلك عندما لم يقلل العلاج السابق من ضغط الدم بما فيه الكفاية.</p><p>سيقوم طبيبك بإرشادك بكيفية التحول من العلاج السابق إلى فيفيزاك بلس.</p><p>طريقة الاعطاء:&nbsp; مخصص فيفيزاك بلس للاستعمال عن طريق الفم.</p><p>يجب بلع الأقراص مع كمية كافية من السوائل مثل كوب&nbsp;واحد من الماء. ي</p><p>مكنك تناول فيفيزاك بلس بغض النظر عن تناول الطعام.</p><p>الخط القاسم على حبه&nbsp;فيفيزاك بلس150/12.5ملغم غير مخصص لتقسيم الحبه إلى جرعات متساوية.</p><p>من المهم أن تستمر في تناول فيفيزاك بلس حتى يخبرك طبيبك خلاف ذلك.</p><p>يجب التوصل للتأثير الأعظم لخافض ضغط الدم خلال 6-8 أسابيع بعد بداية العلاج.</p><p>يجب عدم إعطاء فيفيزاك بلس للأطفال</p><p>يجب عدم إعطاء فيفيزاك بلس للأطفال دون سن 18 سنة من العمر. إذا ابتلع الطفل بعض الأقراص، اتصل بطبيبك على الفور.</p><p>&nbsp;</p><p><strong>أ.إذا تناولت فيفيزاك بلس أكثر مما يجب</strong></p><p>إذا أخذت بطريق الخطأ العديد من الأقراص، اتصل بطبيبك فورا.</p><p><strong>ب. إذا نسيت تناول فيفيزاك بلس</strong></p><p>إذا نسيت عن طريق الخطأ جرعتك اليومية، تناول فقط الجرعة التالية كالمعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p><strong>ج. اذا توقفت عن تناول فيفيزاك بلس</strong></p><p>لا تتوقف عن تناول أقراص فيفيزاك بلس الا إذا أخبرك الطبيب بذلك. يجب التوقف عن تناول أقراص فيفيزاك بلس بشكل تدريجي، خاصة إذا كنت تتناول جرعة عالية، إلا إذا أخبرك طبيبك بخلاف ذلك. قد يؤدي توقف العلاج فجأة إلى إحداث تأثيرات مفاجئة مثل زيادة معدل ضربات القلب وارتفاع ضغط الدم.</p><p>إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>وكما هو الحال في جميع الادوية، يمكن أن يسبب هذا الدواء آثارا جانبية، على الرغم من عدم أصابة الجميع بها.</p><p>بعض هذه الآثار قد تكون خطيرة وقد تتطلب عناية طبية.</p><p>تم الإبلاغ عن حدوث حالات نادرة من تفاعلات حساسية الجلد الطفح الجلدي، الشرى، وكذلك تورم مركز&nbsp;في الوجه، الشفاه و/أو اللسان في المرضى الذين يتناولون اربيسارتان. اذا كان لديك أي من هذه الأعراض أو عانيت من ضيق في التنفس، يجب وقف تناول فيفيزاك بلس والاتصال بطبيبك على الفور.</p><p>تم تعريف تردد الآثار الجانبية المدرجة أدناه باستعمال الاتفاق التالي:</p><p>شائعة جدا: قد تؤثر على الاقل 1 في كل 10 أشخاص او اكثر</p><p>غير شائعة: قد تؤثر إلى ما يصل إلى 1 من كل 100 شخص</p><p>ذكرت الآثار الجانبية في المرضى الذين تم علاجهم مع فيفيزاك بلس:أعراض جانبية شائعة قد تؤثر على 1 من كل 10 اشخاص.</p><p>-غثيان / تقيؤ.</p><p>-تبول غير طبيعي.</p><p>-تعب.</p><p>-دوخة بما في ذلك عند الوقوف من وضع الاستلقاء أو الجلوس.</p><p>-قد تُظهر اختبارات الدم ارتفاع في مستويات الانزيم الذي يقيس وظيفة القلب والعضلات انزيم الكرياتين كيناز أو مستويات مرتفعة من المواد التي تقيس وظيفة الكلى النيتروجين اليوريا والكرياتينين في الدم.إذا كان أي من هذه الآثار الجانبية يسبب لك مشاكل، تحدث مع طبيبك.</p><p>أعراض جانبية غير شائعة قد تؤثر على 1 من كل 100 شخص:</p><p>-الإسهال</p><p>-انخفاض ضغط الدم</p><p>-الإغماء</p><p>-زيادة معدل ضربات القلب</p><p>-إحمرار</p><p>-تورم</p><p>-العجز الجنسي مشاكل مع الأداء الجنسي<br />قد تظهر مستويات منخفضة من البوتاسيوم والصوديوم في اختبارات الدم.إذا كان أي من هذه الآثار الجانبية يسبب لك مشاكل، تحدث مع طبيبك.</p><p>الآثار الجانبية المبلغ عنها منذ إطلاق الدواء:</p><p>تم الإبلاغ عن بعض التأثيرات غير المرغوب فيها منذ تسويق الدواء.</p><p>تأثيرات غير مرغوب فيها حيث لا يعرف التردد هي:</p><p>الصداع ، الرنين في الأذنين ، السعال ، اضطراب الذوق ،عسر الهضم ، ألم في المفاصل والعضلات ، وظائف الكبد غير طبيعية وضعف وظائف الكلى وزيادة مستوى البوتاسيوم في الدم والحساسية مثل الطفح الجلدي وخلايا النحل والتورم في الوجه والشفتين والفم واللسان أو الحلق.</p><p>حالات غير شائعة من اليرقان اصفرار الجلد و/أو بياض العين كما تم الإبلاغ عنها. لأي مزيج من اثنين من المواد الفعالة، لا يمكن استبعاد الآثار الجانبية المرتبطة بكل مكون على حده.</p><p><strong>الآثار الجانبية المرتبطة بإربيسارتان لوحده</strong> بالإضافة إلى الآثار الجانبية المذكورة أعلاه، تم الإبلاغ عن آلام في الصدر وانخفاض في عدد الصفائح الدموية خلية الدم الأساسية لتخثر الدم.<br /><strong>الآثار الجانبية المرتبطة بهيدروكلوروثيازايد لوحده</strong></p><p>&bull;فقدان الشهية</p><p>&bull;تهيج المعدة.</p><p>&bull;تقلصات المعدة</p><p>&bull; إمساك.</p><p>&bull;يرقان اصفرار الجلد و / أو بياض العينين.</p><p>&bull;التهاب البنكرياس والذي يتميز بألم شديد في المعدة من الجهة العليا، وغالبا يصاحبه غثيان وقيء.</p><p>&bull;اضطرابات النوم.</p><p>&bull;كآبة</p><p>&bull;عدم وضوح الرؤية</p><p>&bull; نقص خلايا الدم البيضاء، والتي يمكن أن تؤدي إلى الاصابة بالتهابات متكررة، وحمى.</p><p>&bull;انخفاض في عدد الصفائح الدموية خلية دم ضرورية لتخثر الدم، وانخفاض عدد خلايا الدم الحمراء فقر الدم والتي تتميز بالتعب والصداع، قصر التنفس عند ممارسة الرياضة، الدوخة والشحوب.</p><p>&bull;مرض الكلى.</p><p>&bull;مشاكل في الرئه تتضمن النيمونيا أو تراكم السوائل في الرئتين .</p><p>&bull;مشاكل الرئتين بما فيها التهاب رئوي أو تراكم السوائل في الرئتين.</p><p>&bull;زيادة حساسية الجلد لأشعة الشمس.</p><p>&bull;التهاب الأوعية الدموية.</p><p>&bull;مرض جلدي يتميز بتقشير الجلد في جميع أنحاء الجسم.</p><p>&bull;الذئبة الحمامية الجلدية، والتي يتم تحديدها بسبب الطفح الجلدي الذي قد يظهر على الوجه والرقبة وفروة الرأس.</p><p>&bull;الحساسية.</p><p>&bull;ضعف وتشنج العضلات.</p><p>&bull;تغيير في معدل ضربات القلب</p><p>&bull;انخفاض ضغط الدم بعد تغيير في وضع الجسم.</p><p>&bull;تورم في الغدد اللعابية.</p><p>&bull;ارتفاع مستويات السكر في الدم.</p><p>&bull;طرح السكر في البول</p><p>&bull;ازدياد في بعض أنواع الدهون في الدم.</p><p>&bull;ارتفاع مستويات حمض اليوريك في الدم، والذي قد يسبب النقرس.</p><p><br />ومن المعروف أن الآثار الجانبية المرتبطة بهيدروكلوروثيازايد قد تزيد بتناول جرعات أعلى منه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p>- يحفظ في درجة حرارة لا تتجاوز 30&deg;م م، بعيداً عن الرطوبة.</p><p>-لا تستعمل فيفيزاك بلس بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة Exp. يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.</p><p>-لا تستخدم فيفيزاك بلس إذا لاحظت مواصفات علامات التدهور المرئية.</p><p>-لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: اربيسارتان وهيدروكلوروثيازايد .</p><p>فيفيزاك بلس 150/12.5: كل قرص مغلف يحتوي على 150 ملغم اربيسارتان و12.5 ملغم وهيدروكلوروثيازايد.</p><p>فيفيزاك بلس 300/12.5: كل قرص مغلف يحتوي على 300 ملغم اربيسارتان و12.5 ملغم وهيدروكلوروثيازايد.</p><p>فيفيزاك بلس 300/25: كل قرص مغلف يحتوي على 300 ملغم اربيسارتان و25 ملغم وهيدروكلوروثيازايد.</p><p>المكونات الأخرى هي: لاكتوز، كروسكارميلوز الصوديوم، نشا، هيبروميلوز، سيليلوز دقيق التبلور، ثاني أكسيد السيليكون الغرواني، إستارات المغنيسيوم وأوبادراي أبيض و أكسيد الحديد الأحمر وأكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني :أقراص مغلفة</p><p>الوصف المادي لفيفيزاك بلس:</p><p>فيفيزاك بلس 150/12.5: أقراص متطاولة ذات لون زهري فاتح قابلة للقسم من أحد الجوانب وملساء على الجانب الآخر.</p><p>فيفيزاك بلس 300/12.5: أقراص متطاولة ذات لون مشمشي محدبة الجهتين منقوشة ب U71 على أحد الجوانب وملساء على الجانب الآخر.</p><p>فيفيزاك بلس 300/25: أقراص متطاولة ذات لون أحمر محدبة الجهتين منقوشة ب E43 على أحد الجوانب وملساء على الجانب الآخر.</p><p>أقراص فيفيزاك بلس: معبأة في أشرطة من الألومنيوم و PVC/PVDC، ثم معبأة في علب كرتونية مع نشرة مطوية.</p><p>حجم العبوة: 30 قرص مغلف 10 أقراص / شريط، 3أشرطة / البكيت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك رخصة التسويق :</p><p>الشركة المتحدة لصناعة الأدوية ذ.م.م</p><p>ص.ب. 69، عمان 11591- الأردن</p><p>هاتف: 2901 6 416 962 +</p><p>فاكس: 2905 6 416 962 +</p><p>البريد الإلكتروني: upm_info@mspharma.com</p><p>لأي معلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي للشركة حاملة رخصة التسويق:</p><p>مجموعة سيغالا</p><p>ص ب 19435، جدة 21435-السعودية</p><p>الهاتف: 966126136740+</p><p>فاكس: 96626148458+</p><p>البريد الإلكتروني: ihamidaddin@cigalah.com.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشره بتاريخ Sep., 2017؛ رقم النسخة: 0959-14-M
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VIVAZAC® PLUS 300/12.5 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ﻿Material Name 	Function 	Amount (mg)/one tablet	 
Irbesartan 	Active material 	300.0 	 
Hydrochlorothiazide 	Active material 	12.5 	 
Core In-active ingredients: 	 
Lactose monohydrate 	Diluent 	71.8 	 
Crosscarmellose sodium 	Disintegrant 	36.0 	 
Starch 	Disintegrant 	36.0 	 
Hypromellose 	Binder 	12.0 	 
Microcrystalline cellulose 	Diluent 	121.2 	 
Colloidal silicon dioxide 	Glidant 	4.5 	 
Magnesium stearate  	Lubricant 	6.0 	 
Total before coating 	600 	 
Film coating In-active ingredients : 	 
Opadry White O-YL 28900 	Film coating material 	18.0 	 
Yellow iron oxide 	Coloring agent 	0.07 	 
Red iron oxide 	Coloring agent 	0.108 	 

For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
VIVAZAC® PLUS 300/12.5 F.C. Tablets: Peach, biconvex caplet shape tablet, embossed with U7l on one side and plain on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Orally.</p><p><br /><strong>Posology</strong></p><p>VIVAZAC&reg; PLUS can be taken once daily, with or without food.<br />Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended.<br />When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:<br />- VIVAZAC&reg; PLUS 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;<br />- VIVAZAC&reg; PLUS 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by VIVAZAC&reg; PLUS 150 mg/12.5 mg.<br />- VIVAZAC&reg; PLUS 300 mg/25 mg may be administered in patients insufficiently controlled by VIVAZAC&reg; PLUS 300 mg/12.5 mg.<br />Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended.<br />When necessary, VIVAZAC&reg; PLUS may be administered with another antihypertensive medicinal product.</p><p><u>Special Populations</u><br /><em>Renal impairment: </em></p><p>due to the hydrochlorothiazide component, VIVAZAC&reg; PLUS is not recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Loop diuretics are preferred to thiazides in this population. No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is &ge; 30 ml/min.</p><p><br /><em>Hepatic impairment:</em></p><p>VIVAZAC&reg; PLUS is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function. No dosage adjustment of VIVAZAC&reg; PLUS is necessary in patients with mild to moderate hepatic impairment.</p><p><br /><em>Older people:</em> no dosage adjustment of VIVAZAC&reg; PLUS is necessary in older people.</p><p><br /><em>Paediatric population: </em></p><p>VIVAZAC&reg; PLUS is not recommended for use in children and adolescents because the safety and efficacy have not been established. No data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substances or to any of the excipients, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance)
- Second and third trimesters of pregnancy
- Severe renal impairment (creatinine clearance < 30 ml/min)
- Refractory hypokalemia, hypercalcaemia
- Severe hepatic impairment, biliary cirrhosis and cholestasis
- The concomitant use of VIVAZAC® PLUS with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypotension-Volume-depleted patients:</u> VIVAZAC&reg; PLUS has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension. Symptomatic hypotension may be expected to occur in patients who are volume and/or sodium</p><p>depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. Such conditions should be corrected before initiating therapy with VIVAZAC&reg; PLUS.<br /><u>Renal artery stenosis &ndash; Reno-vascular hypertension: </u>there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme<br />inhibitors or angiotensin-II receptor antagonists. While this is not documented with VIVAZAC&reg; PLUS, a similar effect should be anticipated.<br />Renal impairment and kidney transplantation: when VIVAZAC&reg; PLUS is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended. There is no experience regarding the administration of VIVAZAC&reg; PLUS in patients with a recent kidney transplantation. VIVAZAC&reg; PLUS should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min). Thiazide diuretic-associated azotemia may occur in patients with impaired renal function. No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is &ge; 30 ml/min. However, in patients with mild to moderate renal impairment (creatinine clearance &ge; 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.<br /><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</u><br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended. If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACEinhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.<br /><u>Hepatic impairment:</u> thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. There is no clinical experience with VIVAZAC&reg; PLUS in patients with hepatic impairment.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<br /><u>Primary aldosteronism: </u>patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.</p><p>Therefore, the use of VIVAZAC&reg; PLUS is not recommended.</p><p><u>Metabolic and endocrine effects: </u>thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during thiazide therapy.<br />Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in VIVAZAC&reg; PLUS, minimal or no effects were reported.<br />Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.</p><p><u>Electrolyte imbalance:</u> as for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalemia, hyponatremia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.<br />Although hypokalemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan may reduce diuretic-induced hypokalemia. The risk of hypokalemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH. Conversely, due to the irbesartan component of VIVAZAC&reg; PLUS hyperkalemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with VIVAZAC&reg; PLUS.<br />There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatremia. Chloride deficit is generally mild and usually does not require treatment.<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesemia.</p><p><u>Lithium</u>: the combination of lithium and VIVAZAC&reg; PLUS is not recommended.</p><p><u>Anti-doping test:</u> hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test. <u>General:</u> in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular disease could result in a myocardial infarction or stroke.<br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.<br />Cases of photosensitivity reactions have been reported with thiazides diuretics. If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><u>Pregnancy:</u> Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy&nbsp;should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p><u>Lactose</u>: this medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Acute Myopia and Secondary Acute Angle-Closure Glaucoma:</u> sulfonamide drugs or sulfonamide derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure glaucoma. While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure glaucoma have been reported so far with hydrochlorothiazide. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Other antihypertensive agents: </u></p><p>the antihypertensive effect of VIVAZAC&reg; PLUS may be increased with the concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan with or without thiazide diuretics unless the volume depletion is corrected first.</p><p><u>Aliskiren-containing products or ACE-inhibitors:</u> dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.</p><p><u>Lithium</u>: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with VIVAZAC&reg; PLUS. Therefore, the combination of lithium and VIVAZAC&reg; PLUS is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><u>Medicinal products affecting potassium: </u>the potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, and salt substitutes&nbsp;containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended.</p><p><u>Medicinal products affected by serum potassium disturbances: </u>periodic monitoring of serum potassium is recommended when VIVAZAC&reg; PLUS is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics). Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><u>Additional information on irbesartan interactions:</u> the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by co-administration of irbesartan.</p><p><u>Additional information on hydrochlorothiazide interactions: </u>when administered concurrently, the following medicinal products may interact with thiazide diuretics:<br /><em>Alcohol</em>: potentiation of orthostatic hypotension may occur;<br /><em>Antidiabetic medicinal products (oral agents and insulins):</em> dosage adjustment of the antidiabetic medicinal product may be required;<br /><em>Cholestyramine and Colestipol resins:</em> absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. VIVAZAC&reg; PLUS should be taken at least one hour before or four hours after these medications;<br /><em>Corticosteroids, ACTH: </em>electrolyte depletion, particularly hypokalemia, may be increased;<br /><em>Digitalis glycosides:</em> thiazide induced hypokalemia or hypomagnesemia favor the onset of digitalis-induced cardiac arrhythmias;<br /><em>Non-steroidal anti-inflammatory drugs:</em> the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;<br /><em>Pressor amines (e.g. noradrenaline):</em> the effect of pressor amines may be decreased, but not sufficiently to preclude their use;<br />Nondepolarising skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarising skeletal muscle relaxants may be potentiated by hydrochlorothiazide;<br /><em>Antigout medicinal products: </em>dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of&nbsp;probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol;<br /><em>Calcium salts:</em> thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly;<br /><em>Carbamazepine:</em> concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatremia. Electrolytes should be monitored during concomitant use. If possible, another class of diuretics should be used;<br /><em>Other interactions:</em> the hyperglycemic effect of beta-blockers and diazoxide may be enhanced by thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong>:<br /><em>Angiotensin II Receptor Antagonists (AIIRAs):</em><br />The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy.<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, and hyperkalemia).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension.<br /><em>Hydrochlorothiazide:</em><br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.<br />Since VIVAZAC&reg; PLUS contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.</p><p><strong>Breast-feeding:</strong><br /><em>Angiotensin II Receptor Antagonists (AIIRAs):</em><br />Because no information is available regarding the use of VIVAZAC&reg; PLUS during breast-feeding, VIVAZAC&reg; PLUS is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.<br />It is unknown whether irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk.<br /><em>Hydrochlorothiazide:</em><br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of VIVAZAC&reg; PLUS during breast feeding is not recommended. If VIVAZAC&reg; PLUS is used during breast feeding, doses should be kept as low as possible. Fertility:<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Based on its pharmacodynamic properties, VIVAZAC&reg; PLUS is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide combination:<br />The most commonly reported ADRs were dizziness fatigue, nausea/vomiting and abnormal urination In addition, increases in blood urea nitrogen (BUN) creatine kinase and creatinine were also commonly observed.<br />Table 1 gives the adverse reactions observed.<br />The frequency of adverse reactions listed below is defined using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.<br />Table 1: Adverse Reactions<br />Investigations:<br />Common:<br />increases in blood urea nitrogen (BUN), creatinine and creatine kinase<br />Uncommon:<br />decreases in serum potassium and sodium<br />Confidential<br />Summary of Product Characteristics Page 9 of 16<br />VIVAZAC&reg; PLUS 300/25 Film Coated Tablets April. 11.2016<br />Cardiac disorders:<br />Uncommon:<br />syncope, hypotension, tachycardia, oedema<br />Nervous system disorders:<br />Common:<br />dizziness<br />Uncommon:<br />orthostatic dizziness<br />Not known:<br />headache<br />Ear and labyrinth disorders:<br />Not known:<br />tinnitus<br />Respiratory, thoracic and mediastinal disorders:<br />Not known:<br />cough<br />Gastrointestinal disorders:<br />Common:<br />nausea/vomiting<br />Uncommon:<br />diarrhoea<br />Not known:<br />dyspepsia, dysgeusia<br />Renal and urinary disorders:<br />Common:<br />abnormal urination<br />Not known:<br />impaired renal function including isolated cases of renal failure in patients at risk<br />Musculoskeletal and connective tissue disorders:<br />Uncommon:<br />swelling extremity<br />Not known:<br />arthralgia, myalgia<br />Metabolism and nutrition disorders:<br />Not known:<br />hyperkalemia<br />Vascular disorders:<br />Uncommon:<br />flushing<br />General disorders and administration site conditions:<br />Common:<br />fatigue<br />Immune system disorders:<br />Not known:<br />cases of hypersensitivity reactions such as angioedema, rash, urticaria<br />Hepatobiliary disorders:<br />Uncommon:<br />jaundice<br />Not known:<br />hepatitis, abnormal liver function<br />Reproductive system and breast disorders:<br />Uncommon:<br />sexual dysfunction, libido changes Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with VIVAZAC&reg; PLUS. Tables 2 and 3 below detail the adverse reactions reported with the individual components of VIVAZAC&reg; PLUS.<br />Table 2: Adverse reactions reported with the use of irbesartan alone<br />General disorders and administration site conditions:<br />Uncommon:<br />chest pain<br />Blood and lymphatic system disorders:<br />Not known:<br />thrombocytopenia<br />Table 3: Adverse reactions reported with the use of hydrochlorothiazide alone<br />Investigations:<br />Not known:<br />electrolyte imbalance (including hypokalemia and hyponatremia, , hyperuricemia, glycosuria, hyperglycemia, increases in cholesterol and triglycerides<br />Cardiac disorders:<br />Not known:<br />cardiac arrhythmias<br />Blood and lymphatic system disorders:<br />Not known:<br />aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia<br />Nervous system disorders:<br />Not known:<br />vertigo, paraesthesia, light-headedness, restlessness<br />Eye disorders:<br />Not known:<br />transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma<br />Respiratory, thoracic and mediastinal disorders:<br />Not known:<br />respiratory distress (including pneumonitis and pulmonary oedema)<br />Gastrointestinal disorders:<br />Not known:<br />pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite<br />Renal and urinary disorders:<br />Not known:<br />interstitial nephritis, renal dysfunction<br />Skin and subcutaneous tissue disorders:<br />Not known:<br />anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria<br />Musculoskeletal and connective tissue disorders:<br />Not known:<br />weakness, muscle spasm<br />Vascular disorders:<br />Not known:<br />postural hypotension<br />General disorders and administration site conditions:<br />Not known:<br />fever<br />Hepatobiliary disorders:<br />Not known:<br />jaundice (intrahepatic cholestatic jaundice)<br />Psychiatric disorders:<br />Not known:<br />depression, sleep disturbances<br />The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.</p><p><br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.<br />Confidential<br />Summary of Product Characteristics Page 11 of 16<br />VIVAZAC&reg; PLUS 300/25 Film Coated Tablets April. 11.2016<br />&bull; Toll free phone : 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />- Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with VIVAZAC&reg; PLUS. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.<br />The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia; bradycardia might also occur.<br />Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalemia, hypochloremic, hyponatremia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalemia may result in muscle spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.<br />Irbesartan is not removed by hemodialysis. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: angiotensin-II antagonists, combinations<br />ATC code: C09DA04.<br />VIVAZAC&reg; PLUS is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.<br />Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses in patients without risk of electrolyte imbalance. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.<br />Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte&nbsp;reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics. With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for approximately 6-12 hours.<br />The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.<br />Limited data suggest that patients not controlled with the 300 mg/12.5 mg combination may respond when up titrated to 300 mg/25 mg. In these patients, an incremental blood pressure lowering effect was observed for both systolic blood pressure (SBP) and diastolic blood pressure (DBP).<br />24-hour effects were observed without excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval.<br />The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent after the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 6-8 weeks. In long-term, the effect of irbesartan/hydrochlorothiazide was maintained for over one year. Although not specifically studied with the VIVAZAC&reg; PLUS, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.<br />The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has not been studied. Have shown that long term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.<br />There is no difference in response to VIVAZAC&reg; PLUS, regardless of age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of non-black patients.<br />Efficacy and safety of VIVAZAC&reg; PLUS as initial therapy for severe hypertension (defined as SeDBP &ge; 110 mmHg) was evaluated<br />Patients on the combination achieved trough SeDBP &lt; 90 mmHg compared to of patients on irbesartan. The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively.<br />The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy. During the 8-week treatment period, there were no reported cases of syncope in either treatment group. There were patients with hypotension and of patients with dizziness as adverse reactions reported in the combination and monotherapy groups, respectively.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />No significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.<br />Aliskiren in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints: Cardiovascular death and stroke were both numerically more frequent in the aliskiren group and adverse events and serious adverse events of interest (hyperkalemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the pharmacokinetics of either medicinal product.<br />Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for their activity. Following oral administration of VIVAZAC&reg; PLUS, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively. Food does not affect the bioavailability of VIVAZAC&reg; PLUS. Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and 1-2.5 hours for hydrochlorothiazide.<br />Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood components. The volume of distribution for irbesartan is 53-93 liters. Hydrochlorothiazide is 68% protein-bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for this is unknown. The total body and renal clearance are 157-176 and 3.0-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. Somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects (&ge; 65 years) than those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people. The mean plasma half-life of hydrochlorothiazide reportedly ranges from 5-15 hours.<br />Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or intravenous administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidneys. At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier, and is excreted in breast milk.</p><p>Renal impairment: in patients with renal impairment or those undergoing hemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by hemodialysis. In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.</p><p><br />Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. Studies have not been performed in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Irbesartan/hydrochlorothiazide:</u> the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months. There were no toxicological findings observed of relevance to human therapeutic use.<br />The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicological interactions were observed):<br />- Kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;<br />- Slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);<br />- Stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;<br />- Decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan.<br />Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing cells) and occur also with angiotensin converting enzyme inhibitors. These findings appear to have no relevance to the use of therapeutic doses of irbesartan/hydrochlorothiazide in humans.<br />No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity. The effects of the irbesartan/hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone. However, another angiotensin-II antagonist affected fertility parameters in animal studies when given alone. These findings were also observed with lower doses of this other angiotensin-II antagonist when given in combination with hydrochlorothiazide.<br />There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide combination. The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not been evaluated in animal studies.<br /><u>Irbesartan:</u> there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats&nbsp;and &ge; 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, hemoglobin, hematocrit). At very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.<br />Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabeled irbesartan is detected in rat and rabbit fetuses. Irbesartan is excreted in the milk of lactating rats.<br />Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydro ureter or subcutaneous oedema) in rat fetuses, which were resolved after birth. In rabbits, abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.<br /><u>Hydrochlorothiazide:</u> although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate,<br />Crosscarmellose sodium,<br />Starch,<br />Hypromellose,<br />Microcrystalline Cellulose,<br />Colloidal silicon dioxide,<br />Magnesium Stearate,<br />Opadry White O-YL 28900,<br />Yellow Iron Oxide &amp;<br />Red Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store up to 30&deg;C, protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VIVAZAC&reg; PLUS 300/12.5 F.C. Tablets: are packed in blisters (Aluminum foil &amp; PVC coated PVDC) then packed in cardboard cartons with a multi-folded leaflet.<br />Pack size: 30 F/C Tablets; (10 F/C Tablets /blister, 3 blisters/ pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901
Fax: + 962 (6) 416 2905
E-mail: Info@upm.com.jo
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September, 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>